123). It can be noteworthy that GLS2 is tumorigenic in breast cancer124, and its expression could compensate for loss of Gls in MYC-induced mouse liver tumours40. This implies that GLS2 could confer resistance to GLS1-specific inhibitors, like the allosteric inhibitor BPTES or CB-839, which resistance might be hypothetically prevented by https://laneipudg.getblogs.net/61579821/detailed-notes-on-e-64